Multiepitope CD8+ T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting
Valérie Dutoit, Robert N. Taub, Kyriakos P. Papadopoulos, Susan Talbot, Mary-Louise Keohan, Michelle Brehm, Sacha Gnjatic, Paul E. Harris, Brygida Bisikirska, Philippe Guillaume, Jean-Charles Cerottini, Charles S. Hesdorffer, Lloyd J. Old, Danila Valmori
Valérie Dutoit, Robert N. Taub, Kyriakos P. Papadopoulos, Susan Talbot, Mary-Louise Keohan, Michelle Brehm, Sacha Gnjatic, Paul E. Harris, Brygida Bisikirska, Philippe Guillaume, Jean-Charles Cerottini, Charles S. Hesdorffer, Lloyd J. Old, Danila Valmori
View: Text | PDF
Article Immunology

Multiepitope CD8+ T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting

Abstract

Research Article

Authors

Valérie Dutoit, Robert N. Taub, Kyriakos P. Papadopoulos, Susan Talbot, Mary-Louise Keohan, Michelle Brehm, Sacha Gnjatic, Paul E. Harris, Brygida Bisikirska, Philippe Guillaume, Jean-Charles Cerottini, Charles S. Hesdorffer, Lloyd J. Old, Danila Valmori

×

Figure 3

Options: View larger image (or click on image) Download as PowerPoint
Fine specificity of antigen recognition and tumor reactivity of distinct...
Fine specificity of antigen recognition and tumor reactivity of distinct NY-ESO-1 multimer+ CTL recognizing overlapping epitopes in the 157-167 region. (a) Recognition of NY-ESO-1 peptides by polyclonal monospecific multimer+–sorted populations as well as by the NY-ESO-1–specific tumor-reactive clone LAU 156/5 used as an internal control was assessed in a 51Cr release assay on T2 target cells in the presence of graded concentration of the indicated peptides. (b) Tumor recognition was similarly assessed on Me 275 (A2+ NY-ESO-1+) or Me 260 (A2–) tumor target cells at the indicated E/T ratio.